Despite warnings, potentially inappropriate CNS-active medications are commonly prescribed to older adults — especially those with cognitive impairment — highlighting missed opportunities for safer ...
Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment of BBB shuttle–siRNA ...
MedPage Today on MSN
Risky drugs still in the mix for dementia patients
Questionable prescribing of CNS-active drugs persists ...
Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...
Zidovudine PBCA and MMA-SPM Emulsion polymerization and free-radical polymerization PBCA as a carrier; alcohol increases permeability of BMVECs to NPs [114] Indinavir Drug nanocrystals and lipoid E80 ...
Delivering therapies to the brain remains a major challenge due to the limited permeability of the blood-brain barrier. In a ...
FREMONT, CA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (ABVC) (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company ...
Compared to Black and Asian people, white and Hispanic people with Alzheimer's disease and related dementias were most likely to be diagnosed with symptoms like depression and agitation, according to ...
Sage Therapeutics has been working in the area of steroid-derived compounds that affect CNS receptor signaling. A pivotal trial failed to show benefit, and they had several other clinical failures as ...
Avadel Pharmaceuticals plc has published six manuscripts in a CNS Drugs supplement titled "A New Dawn in the Management of Narcolepsy," focusing on clinical management strategies, shared ...
LONDON, Dec 13 (Reuters) - GlaxoSmithKline Plc said on Thursday its neuroscience drug development programme had made significant advances, though development of a closely watched experimental insomnia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results